Navigation Links
WuXi PharmaTech to Present at 20th Annual Piper Jaffray Healthcare Conference
Date:11/27/2008

SHANGHAI, China, Nov. 27 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced Edward Hu, the Company's Chief Operating Officer, will present at the 20th Annual Piper Jaffray Healthcare Conference on Wednesday, December 3, 2008, at 12:00 pm Eastern Standard Time.

(Photo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The Company will broadcast its presentation. Interested parties may access the broadcast through the Investor Relations section of the Company's web site: http://www.wuxiapptec.com .

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

    Form more information, please contact:

     Debra Yu, MD
     Vice President Strategy
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-215-218-5559
     Email: ir@wuxiapptec.com

     Dr. Hai Mi
     Executive Director of Investor Relations and Business Planning
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +86-21-5046-3726
     Email: ir@wuxiapptec.com

     Juliane Snowden
     Vice President of Investor Relations
     Burns McClellan
     Tel:   +1-212-213-0006
     Email: Jsnowden@burnsmc.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. WuXi PharmaTech Expands Collaboration for Fully Integrated Services
2. WuXi PharmaTech Announces Second Quarter 2008 Results
3. WuXi PharmaTech (NYSE: WX) Appoints Mr. Steven M. Hutchins as VP of Business Development
4. Dr. Richard M. Soll Joined WuXi PharmaTech (NYSE: WX) as VP of Medicinal Chemistry
5. WuXi PharmaTech 2007 Annual Report Available Online
6. The First QPatch HT in China Placed in WuXi PharmaTech (NYSE: WX)
7. Stanford Professor Barry M. Trost Visits WuXi PharmaTech and Gives Two Seminars
8. WuXi PharmaTech Announces Postponement of Proposed Follow-on Offering
9. Princeton Professor David W. C. MacMillan Lectured WuXi PharmaTech Scientists
10. WuXi PharmaTech (NYSE: WX) Names Temporary Chairman of the Audit Committee
11. WuXi PharmaTech (NYSE: WX) Mourns the Tragic Loss of Its Independent Director Shawn Wang
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , ... March 29, 2017 , ... During the last ... provide free screening colonoscopies to eligible individuals in the local community. , Colon ... but regular screenings can detect colon cancer while it is small, confined and easier ...
(Date:3/29/2017)... , ... March 29, 2017 , ... Full Contact K9, ... of Pet Protect Law that assists dog owners in creating legally-enforceable pet ... owners in taking the natural next step to protect their new companion. Says Evan ...
(Date:3/29/2017)... Petersburg, FL (PRWEB) , ... March 30, 2017 , ... ... called the "Spice of Life" or "Wonder Spice", it has been used for thousands ... use in the East," says Heshelow, author of " Turmeric: How to Use it ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Wall Centre Dental ... new patients from Burnaby, BC. Patients in need of experienced orthodontics, laser dentistry, ... see the esteemed team at Wall Centre Dental. Drs. Parviz Roshan, Siamak Tehrani, ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... as it continues developing an ANSI-approved, consensus-based American National Standard for Good ... to publish the first ANSI-approved GMP standard for dietary supplements this spring, ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017  The Global ... Japanese public-private partnership formed to battle infectious diseases ... totaling US$23 million* that could help deliver a ... of debilitating conditions. This latest ... Phase 3 clinical trial testing a pediatric formulation ...
(Date:3/29/2017)... TREE, Colo. , March 29, 2017  Zynex (OTCQB: ... manufacture and sale of non-invasive medical devices for pain ... today that it will host the Company,s 2016 full-year ... a.m. Eastern Time.) The Company expects to ... 31, 2017. ...
(Date:3/29/2017)... 29, 2017  Glenmark Pharmaceuticals, a global pharmaceutical ... an investigational fixed-dose combination of mometasone furoate (25 ... as a nasal spray being studied for the ... from a recently completed Phase 3 trial assessing ... therapy versus mometasone, olopatadine or placebo. ...
Breaking Medicine Technology: